drugset / Trial / NCT02231775

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

NCT02231775 ↗

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm phase II trial focused on how dabrafenib and trametinib before and after surgery works in treating patients with stage IIIB-C melanoma that has a specific mutation in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving dabrafenib and trametinib after surgery may kill any remaining tumor cells.

Timeline

Start
2014-10-22
Primary completion
2027-04-01
Completion
2027-04-01

Outcome

Met primary endpoint

paper Neoadjuvant plus adjuvant dabrafenib and trametinib significantly improved event-free survival versus standard of care PMID 29361468 ↗

paper hazard ratio 0·016, 95% CI 0·00012-0·14, p<0·0001 PMID 29361468 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabrafenib Small molecule 150 mg Oral
Subject Trametinib Small molecule 2 mg Oral

Indications